NZ's AFT Pharmaceuticals rises on licensing deal for epilepsy therapy

AFT Pharmaceuticals

21/07/2023 03:41

** Shares of AFT Pharmaceuticals  AFT.NZ  gains 1.9% to
NZ$3.75, marking their biggest intraday fall since July 11 
    ** Drugmaker says it has signed licensing deal for sale of
epilepsy therapy Zeneo Midazolam in Australia and New Zealand
    ** Licensing deal signed with French pharmaceutical co
Crossject SA  74C.F  
    ** Therapy used for treatment of status epilepticus, which
are epileptic seizures that last longer than five minutes
    ** Friday's stock rise adds to yearly gains of 2.7%

 (Reporting by Harish Sridharan in Bengaluru)
 ((harish.sridharan@thomsonreuters.com))